Marta Klisinska, MD
Internal Medicine · St Augustine, FLNPI 1720491251
Payments from drug & device makers
Across 293 payments — averaging $29.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Boehringer Ingelheim$709
- GSK$661
- Medtronic$576
- Lilly USA, LLC$476
- plus $3K from 32 others
What the payments were for
- Food & beverage$8,577100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $1,634 |
| Novo Nordisk | 48 | $1,193 |
| Boehringer Ingelheim | 31 | $709 |
| GSK | 24 | $661 |
| Medtronic(2 entities) | 8 | $576 |
| Lilly USA, LLC | 24 | $476 |
| Johnson & Johnson(2 entities) | 7 | $392 |
| Amgen(2 entities) | 7 | $385 |
| Pfizer | 22 | $345 |
| Sanofi-aventis U.S. LLC | 18 | $300 |
| Abbott | 6 | $220 |
| AbbVie(2 entities) | 7 | $200 |
| Atricure, Inc. | 1 | $157 |
| Cequr Corporation | 1 | $143 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Silk Road Medical, Inc. | 1 | $116 |
| Amarin Pharma, Inc. | 1 | $114 |
| Merck | 7 | $113 |
| Stryker | 1 | $103 |
| Astellas Pharma US Inc | 4 | $91 |
| Intuitive Surgical | 1 | $86 |
| Exact Sciences | 5 | $86 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Daiichi Sankyo Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $37 |
| BD | 1 | $36 |
| Eisai Inc. | 2 | $34 |
| Bayer | 2 | $31 |
| Seqirus USA Inc | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Gilead | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $13 |
| Exeltis, USA Inc. | 1 | $11 |
| Cvrx, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$365
- FARXIGA$359
- AIRSUPRA$249
- ENROUTE Transcarotid Neuroprotection System$231
- INCEPTIV$159
- SYNERGY ABLATION SYSTEM$157
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2)$157
- Repatha$146
- CeQur Simplicity$143
- ClosureFast$128
- FREESTYLE LIBRE 3$126
- Ozempic$125
- AREXVY$125
- VOQUEZNA$125
- ZEPBOUND$124
- XARELTO$123
- Xultophy 100/3.6$123
- Wegovy$122
- RYBELSUS$122
- Otezla$121
How this compares
$8,598 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 112 | $149,292 |
| OzempicSemaglutide | 73 | $86,656 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $63,939 |
| FarxigaDapagliflozin Propanediol | 63 | $63,035 |
| TrulicityDulaglutide | 36 | $47,668 |
| JanuviaSitagliptin Phosphate | 30 | $46,148 |
| MounjaroTirzepatide | 33 | $37,848 |
| EliquisApixaban | 21 | $28,148 |
| LinzessLinaclotide | 27 | $20,749 |
| TradjentaLinagliptin | 18 | $17,753 |
| XareltoRivaroxaban | 11 | $12,645 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,118 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,121 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,693 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $4,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $709 | $167,045130 claims |
| Novo NordiskOzempic | $1,193 | $86,65673 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $476 | $85,51669 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,634 | $77,84691 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $661 | $71,06077 claims |
| MerckJanuvia | $113 | $46,14830 claims |
| PfizerEliquis | $345 | $28,14821 claims |
| AbbVieLinzess, Synthroid | $200 | $23,21453 claims |
| Johnson & JohnsonXarelto | $392 | $12,64511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in St Augustine
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.